Clinical Trials Browser

Phase 2 × lorlatinib × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT07415005 2026-02-17

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Advanced Non-Small Cell Lung Cancer

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

Non Small Cell Lung Cancer Metastatic

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04111705 2025-04-01

ORAKLE

Phase 2 Completed

Non Small Cell Lung Cancer Metastatic

NCT06682884 2024-11-12

NEOLORA

Phase 2 Not yet recruiting

Neoadjuvant Non-Small Cell Lung Cancer

NCT04127110 2024-11-05

ALKALINE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06378892 2024-04-23

ALK-PPL

Phase 2 Recruiting

Non Small Cell Lung Cancer Metastatic

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer

NCT03505554 2023-08-07

CRU3

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms